Sugi Predict

Sugi Predict / Compounds / SCHEMBL247794

SCHEMBL247794

SCHEMBL247794

O=[N+]([O-])c1ccccc1Nc1ccc(Cl)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.74
▸ MAPK1 P28482 4/20 0.74
▸ TDP1 Q9NUW8 4/20 0.74
▸ ALDH1A1 P00352 4/20 0.74
▸ CASP7 P55210 1/20 0.74
▸ MAPT P10636 9/20 0.71
▸ MEN1 O00255 4/20 0.71
▸ KMT2A Q03164 4/20 0.71
▸ GAA P10253 2/20 0.71
▸ PKM P14618 1/20 0.71
▸ EPAS1 Q99814 1/20 0.64
▸ PHGDH O43175 1/20 0.59
▸ IDO1 P14902 1/20 0.56
▸ LMNA P02545 2/20 0.52
▸ MAPK13 O15264 1/20 0.52
▸ MAPK12 P53778 1/20 0.52
▸ MAPK11 Q15759 1/20 0.52
▸ MAPK14 Q16539 1/20 0.52
▸ RAB9A P51151 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3912077 0.91 L3MBTL1 (0.62) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL11506844 0.91 ALDH1A1 (0.89) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL6652722 0.90 PHGDH (0.64) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL11507400 0.86 ALDH1A1 (0.79) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL31333098 0.85 TDP1 (1.00) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL230292 0.85 TDP1 (1.00) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL27504611 0.85 L3MBTL1 (0.54) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL5718635 0.84 MAPK1 (0.77) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL16291325 0.84 TDP1 (0.55) L3MBTL1MAPK1TDP1ALDH1A1CASP7
SCHEMBL11383159 0.83 L3MBTL1 (0.82) L3MBTL1MAPK1TDP1ALDH1A1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507189-A Chemically synthesized bulk drug and application thereof in treating tuberculosis and drug-resistant tuberculosis 余述南 2022-05-17 — — CN claimed
CN-120698941-A Preparation method of high-purity clofazimine 山西立业制药有限公司 2025-09-26 — — CN disclosed
CN-119985760-A High performance liquid chromatography detection method for clofazimine intermediate 山西立业制药有限公司 2025-05-13 — — CN disclosed
CN-114507189-A Chemically synthesized bulk drug and application thereof in treating tuberculosis and drug-resistant tuberculosis 余述南 2022-05-17 — — CN disclosed
CN-114380767-A Thiazole amide compound containing diphenylamino group and preparation method and application thereof 安徽理工大学 2022-04-22 — — CN disclosed
CN-113454057-A Intermediate for preparing phenazine derivative and preparation method thereof ST制药株式会社 2021-09-28 — — CN disclosed
WO-2020166984-A1 INTERMEDIATE FOR PRODUCING PHENAZINE DERIVATIVE, AND METHOD FOR PRODUCING SAME 에스티팜 주식회사 2020-08-20 — — WO disclosed
WO-2020166984-A1 INTERMEDIATE FOR PRODUCING PHENAZINE DERIVATIVE, AND METHOD FOR PRODUCING SAME 에스티팜 주식회사 2020-08-20 — — WO disclosed
EP-2705039-B1 BROMODOMAIN INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2017-07-26 — — EP disclosed
US-9540336-B2 Therapeutic agents THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2017-01-10 — — US disclosed
EP-2705039-A2 BROMODOMAIN INHIBITORS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2014-03-12 — — EP disclosed
EP-2588470-A1 RIMINOPHENAZINES WITH 2-(HETEROARYL)AMINO SUBSTITUENTS AND THEIR ANTI-MICROBIAL ACTIVITY Global Alliance For Tb Drug Development (US) 2013-05-08 — — EP disclosed
WO-2012151512-A2 BROMODOMAIN INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2012-11-08 — — WO disclosed
US-20120071472-A1 RIMINOPHENAZINES WITH 2-(HETEROARYL)AMINO SUBSTITUENTS AND THEIR ANTI-MICROBIAL ACTIVITY INSTITUTE OF MATERIA MEDICA (CN) 2012-03-22 — — US disclosed
US-20120071472-A1 RIMINOPHENAZINES WITH 2-(HETEROARYL)AMINO SUBSTITUENTS AND THEIR ANTI-MICROBIAL ACTIVITY INSTITUTE OF MATERIA MEDICA (CN) 2012-03-22 — — US disclosed
WO-2012003190-A1 RIMINOPHENAZINES WITH 2-(HETEROARYL)AMINO SUBSTITUENTS AND THEIR ANTI-MICROBIAL ACTIVITY GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) 2012-01-05 — — WO disclosed
US-6403607-B1 ANTIULCER Hidaka, Hiroyoshi (JP) 2002-06-11 — — US disclosed
EP-1072587-A1 SULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Hidaka, Hiroyoshi (JP) 2001-01-31 — — EP disclosed
US-4510141-A (1,2,4) TRIAZOLO(1,5-A) QUINOXALINE OR PYRIDO(2,3-E)(U,2,4)TRIAZOLO(1,5-A)PYRAZINE COMPOUNDS CIBA-GEIGY CORPORATION (US) 1985-04-09 — — US disclosed
EP-0074929-A1 Polycyclic polyazaheterocycles, process for their preparation and pharmaceutical preparations containing them CIBA-GEIGY AG (CH) 1983-03-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071472-A1 RIMINOPHENAZINES WITH 2-(HETEROARYL)AMINO SUBSTITUENTS AND THEIR ANTI-MICROBIAL ACTIVITY TYR, RABGGTB, RAB35 L3MBTL1 3119/4885MAPK1 2560/4885TDP1 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.